Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.

World journal of gastroenterology - 21 Jul 2017

Netz Uri, Carter Jane Victoria, Eichenberger Maurice Robert, Dryden Gerald Wayne, Pan Jianmin, Rai Shesh Nath, Galandiuk Susan

Abstract excerpt

AIM: To investigate genetic factors that might help define which Crohn's disease (CD) patients are likely to benefit from anti-tumor necrosis factor (TNF) therapy. METHODS: This was a prospective cohort study. Patients were recruited from a university digestive disease practice database. We included CD patients who received anti-TNF therapy, had available medical records (with information on treatment duration...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adalimumab
Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonoscopy

Share to Crohn Disease

Share to Fas Ligand Protein

Share to Gastrointestinal Agents

Share to Infliximab

Share to Tumor Necrosis Factor-alpha

Source

Open in PubMed Open full text

Identifiers

PMID: 28785150
DOI: 10.3748/wjg.v23.i27.4958
PMCID: PMC5526766

Genes

TNF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease.PMID 28785150Read ↗

Systematic review: genetic biomarkers associated with anti-TNF treatment response in inflammatory bowel diseases.Semantic proximity Read ↗

A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism.Semantic proximity Read ↗

Variants of the CASP9 gene as candidate markers for primary response to anti-TNF therapy in Crohn's disease patientsSemantic proximity Read ↗

Pharmacogenetic biomarkers of response in Crohn's disease.Semantic proximity Read ↗

Genetic Markers Predict Primary Non-Response and Durable Response To Anti-TNF Biologic Therapies in Crohn's Disease.Semantic proximity Read ↗

Genetically determined high activity of IL-12 and IL-18 in ulcerative colitis and TLR5 in Crohns disease were associated with non-response to anti-TNF therapy.Semantic proximity Read ↗

Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes.Semantic proximity Read ↗

Polymorphisms in apoptosis genes predict response to infliximab therapy in luminal and fistulizing Crohn's disease.Semantic proximity Read ↗

Genetic polymorphisms in tumour necrosis factor receptors (TNFRSF1A/1B) illustrate differential treatment response to TNFα inhibitors in patients with Crohn’s diseaseSemantic proximity Read ↗

Association between Genetic Polymorphisms and Response to Anti-TNFs in Patients with Inflammatory Bowel Disease.Semantic proximity Read ↗

Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis.Semantic proximity Read ↗

Associations between functional polymorphisms in the NFκB signaling pathway and response to anti-TNF treatment in Danish patients with inflammatory bowel disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.